Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.53 |
| ▸ | MTOR | P42345 | 13/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.53 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.53 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.53 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336616 | 0.92 | PIK3CA (0.55) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL336326 | 0.90 | PIK3CA (0.53) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL336553 | 0.88 | PIK3CA (0.53) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL337330 | 0.87 | PIK3CA (0.55) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL336741 | 0.86 | PIK3CA (0.53) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL799565 | 0.86 | PIK3CA (0.52) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL799553 | 0.86 | PIK3CA (0.51) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL336652 | 0.85 | PIK3CA (0.53) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL337082 | 0.84 | PIK3CA (0.58) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL336159 | 0.84 | PIK3CA (0.52) | PIK3CAMTORPIK3CBPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2336132-B1 | MORPHOLINOPURINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2014-01-01 | — | — | EP | disclosed |
| US-8309546-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-8309546-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-8309546-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8097622-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097622-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097622-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-17 | — | — | US | disclosed |
| EP-2336132-A1 | MORPHOLINOPURINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | PIK3CA 22/4885MTOR 1/4885PIK3CB 102/4885 |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | PIK3CA 22/4885MTOR 1/4885PIK3CB 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.